Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the Government plans to procure the Evusheld drug for treatment of covid-19 for clinically extremely vulnerable people.

On 17 March 2022, Evusheld was granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency (MHRA). However, the MHRA highlighted uncertainty over the appropriate dose needed for protection against the Omicron variant. Understanding its efficacy is necessary prior to any procurement or deployment decisions. The UK Health Security Agency is currently undertaking further testing on the treatment’s effectiveness against the Omicron variant to inform any such decisions.